Close Menu

NEW YORK – Thermo Fisher Scientific said on Thursday that its offer to acquire all ordinary shares of Qiagen has lapsed and that it has terminated the acquisition agreement with the company.

As a result, Qiagen will pay Thermo Fisher $95 million in cash as expense reimbursement, as stipulated by the terms of the acquisition agreement.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.